Almirall acquires Poli Group and with it Ciclopoli a leading drug for onychomycosis.

Almirall, S.A. the global pharmaceutical company based in Barcelona, announces that it has signed an agreement to acquire one hundred per cent of the share capital of Poli Group Holding S.r.l., the holding company of Poli Group. Poli Group comprises three operating companies (Taurus Pharma GmbH, Polichem S.A. and Polichem S.r.l). With this strategic transaction Almirall continues to execute on the plan to become a top global Dermatology player announced last year after the transfer agreement with AstraZeneca. Poli Group has a diversified and growing portfolio of proprietary and well-established drugs, focused on Dermatology and complemented with a strong portfolio of Gynaecology and Respiratory products, the latter promoted through distributors. The acquired brands include Ciclopoli, the flagship product that has led Poli Group to become a world leader in nail diseases (onychomycosis), a large and underserved market affecting approximately 10-15% of the total population. Other main Dermatology products include Sililevo and Zeloglin, used to treat nail psoriasis and rosacea.